This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Asahi Kasei Pharma Corporation
ClinicalTrials.gov Identifier:
NCT00902369
First received: May 14, 2009
Last updated: July 21, 2016
Last verified: July 2010
  Purpose
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study

Condition Intervention Phase
Rheumatoid Arthritis Drug: AK106-001616 Drug: Placebo Drug: Active comparator Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Asahi Kasei Pharma Corporation:

Estimated Enrollment: 130
Study Start Date: May 2009
Study Completion Date: July 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AK106-001616 Drug: AK106-001616
Part1: Dose escalation Part2: Dose expansion
Placebo Comparator: Placebo
Part1: AK106-001616 and Placebo
Drug: Placebo
Active Comparator: Active comparator
Part2: AK106-001616 and Active comparator
Drug: Active comparator

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of RA (class I to III)
  • Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Abnormal screening laboratory test values considered to be clinically significant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00902369

Locations
Czech Republic
Hlucin, Czech Republic
Praha 2, Czech Republic
Uherske Hradiste, Czech Republic
Germany
Frankfurt, Hessen, Germany
Berlin, Germany
Hamburg, Germany
Hungary
Budapest, Hungary
Érd, Hungary
Lithuania
Vilnius, Lithuania
Romania
Bucharest, Romania
United Kingdom
Cambridge, Cambridgeshire, United Kingdom
Sheffield, South Yorkshire, United Kingdom
Sponsors and Collaborators
Asahi Kasei Pharma Corporation
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Asahi Kasei Pharma Corporation
ClinicalTrials.gov Identifier: NCT00902369     History of Changes
Other Study ID Numbers: AK106 II-01
Study First Received: May 14, 2009
Last Updated: July 21, 2016

Keywords provided by Asahi Kasei Pharma Corporation:
AK106-001616

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on September 21, 2017